Common Contracts
144 similar Purchase Agreement contracts by CymaBay Therapeutics, Inc., Motus GI Holdings, Inc., OncoCyte Corp, others
12,551,080 Shares1 Pre-Funded Warrants to Purchase Up to 583,771 Shares of Common Stock CymaBay Therapeutics, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • September 12th, 2023 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
CymaBay Therapeutics, Inc., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 12,551,080 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company and pre-funded warrants (the “Warrants”) to purchase up to an aggregate of 583,771 shares of Common Stock in the form attached here to as Exhibit A. The Firm Shares consist of 12,551,080 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,970,227 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively referred to as the “Shares.” The Shares and the Warrants are herein referred to as the “S
10,000,000 Shares1 Pre-Funded Warrants to Purchase Up to 2,142,857 Shares of Common Stock CymaBay Therapeutics, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • January 25th, 2023 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
CymaBay Therapeutics, Inc., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 10,000,000 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company and pre-funded warrants (the “Warrants”) to purchase up to an aggregate of 2,142,857 shares of Common Stock in the form attached here to as Exhibit A. The Firm Shares consist of 10,000,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,821,428 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively referred to as the “Shares.” The Shares and the Warrants are herein referred to as the
13,900,000 Shares1 POINT Biopharma Global Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • September 14th, 2022 • POINT Biopharma Global Inc. • Pharmaceutical preparations • New York
PIPER SANDLER & CO. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen:
15,625,000 Shares1 Pre-Funded Warrants to Purchase Up to 3,125,000 Shares of Common Stock CymaBay Therapeutics, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • November 18th, 2021 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
CymaBay Therapeutics, Inc., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,625,000 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company and pre-funded warrants (the “Warrants”) to purchase up to an aggregate of 3,125,000 shares of Common Stock in the form attached here to as Exhibit A. The Firm Shares consist of 15,625,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 2,812,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively referred to as the “Shares.” The Shares and the Warrants are herein referred to as the
●] American Depositary Shares1 MDxHealth SA PURCHASE AGREEMENTPurchase Agreement • October 28th, 2021 • MDxHealth SA • Services-medical laboratories • New York
MDxHealth SA, a limited liability company (naamloze vennootschap/société anonyme) organized under the laws of Belgium (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] American Depositary Shares (the “ADSs”), each representing ten new ordinary shares to be issued without nominal value (the “Ordinary Shares”), of the Company. The [●] ADSs to be sold by the Company are called the “Firm ADSs.” The Company has also granted to the Underwriters an option to purchase up to [●] additional ADSs on the terms and for the purposes set forth in Section 3 hereof (the “Option ADSs”). The Firm ADSs and any Option ADSs purchased pursuant to this Purchase Agreement (the “Agreement”) are herein collectively called the “Securities.”
8,400,000 Shares1 Apollo Endosurgery, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • October 14th, 2021 • Apollo Endosurgery, Inc. • Surgical & medical instruments & apparatus • New York
Apollo Endosurgery, Inc., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 8,400,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,260,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
9,375,000 Shares ATYR PHARMA, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • September 16th, 2021 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
aTyr Pharma, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,375,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 9,375,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,406,250 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
● ] Shares[1] Nyxoah SA Ordinary Shares PURCHASE AGREEMENTPurchase Agreement • June 25th, 2021 • Nyxoah SA • Surgical & medical instruments & apparatus • New York
Nyxoah SA, a limited liability company (naamloze vennootschap/société anonyme) organized under the laws of Belgium (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ● ] Ordinary Shares (the “Firm Shares”), with no nominal value (the “Ordinary Shares”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to [ ● ] additional Ordinary Shares on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
EDAP TMS S.A. 4,150,000 American Depositary Shares Representing 4,150,000 Ordinary Shares (Nominal Value €0.13 per share) PURCHASE AGREEMENTPurchase Agreement • April 26th, 2021 • Edap TMS Sa • Electromedical & electrotherapeutic apparatus • New York
The ADSs delivered to the Underwriters hereunder shall be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to the Deposit Agreement (the “Deposit Agreement”) dated as of July 31, 1997 and amended and restated as of April 7, 2008, by and among the Company, The Bank of New York Mellon, as depositary (the “Depositary”) and all owners and beneficial owners from time to time of the ADRs.
28,572,000 Shares1 Marker Therapeutics, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • March 16th, 2021 • Marker Therapeutics, Inc. • Pharmaceutical preparations • New York
Marker Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 28,572,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 28,572,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 4,285,800 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
3,500,000 Shares1 Digi International Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • March 5th, 2021 • Digi International Inc • Computer communications equipment • New York
Digi International Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,500,000 shares (the “Firm Shares”) of Common Stock, $0.01 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 3,500,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 525,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
2,795,000 Shares AVITA Medical, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • March 1st, 2021 • AVITA Medical, Inc. • Surgical & medical instruments & apparatus • New York
AVITA Medical, Inc., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,795,000 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 419,250 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
1,714,000 Shares1 Celcuity Inc. Common Stock, par value $0.001 per share PURCHASE AGREEMENTPurchase Agreement • February 24th, 2021 • Celcuity Inc. • Services-medical laboratories • New York
Celcuity Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,714,000 shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 257,100 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
PURCHASE AGREEMENTPurchase Agreement • February 12th, 2021 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 21,000,000 shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 21,000,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 3,150,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
8,947,000 Shares OncoCyte Corporation Common Stock PURCHASE AGREEMENTPurchase Agreement • February 5th, 2021 • OncoCyte Corp • In vitro & in vivo diagnostic substances • New York
OncoCyte Corporation, a California corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 7,780,000 shares (the “Firm Shares”) of Common Stock, no par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 7,780,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,167,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
4,840,000 Shares NEURONETICS, INC. Common Stock, $0.01 par value per share PURCHASE AGREEMENTPurchase Agreement • February 2nd, 2021 • Neuronetics, Inc. • Surgical & medical instruments & apparatus • New York
Neuronetics, Inc., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,840,000 shares (the “Firm Shares”) of common stock, $0.01 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 4,840,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 726,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
3,225,000 Shares1 Qumu Corporation Common Stock, par value $0.01 per share PURCHASE AGREEMENTPurchase Agreement • January 27th, 2021 • Qumu Corp • Services-prepackaged software • New York
Qumu Corporation, a Minnesota corporation (the “Company”), proposes to sell to Craig-Hallum Capital Group LLC (the “Underwriter”) an aggregate of 3,225,000 shares (the “Firm Shares”) of Common Stock, par value $0.01 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriter an option to purchase up to 483,750 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
🌑 ] Shares Progenity, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • December 1st, 2020 • Progenity, Inc. • Services-medical laboratories • New York
Progenity, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ 🌑 ] shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of [ 🌑 ] authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to [ 🌑 ] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
3,125,000 Shares Repro Med Systems, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • June 22nd, 2020 • Repro Med Systems Inc • Surgical & medical instruments & apparatus • New York
Repro Med Systems, Inc., a New York corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Piper Sandler & Co. and Canaccord Genuity LLC are acting as representatives (in such capacity, the “Representatives”), an aggregate of 3,125,000 shares (the “Firm Shares”) of Common Stock, $0.01 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to an aggregate of 468,750 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
●] Shares Progenity, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • June 15th, 2020 • Progenity, Inc. • Services-medical laboratories • New York
Progenity, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of [●] authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
EXECUTION VERSION 6,666,667 Shares Motus GI Holdings, Inc. Common Stock PURCHASE AGREEMENT June 26, 2019 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. Minneapolis, Minnesota 55402...Purchase Agreement • May 5th, 2020 • New York
Motus GI Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,666,667 shares (the “Firm Shares”) of Common Stock, $.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 6,666,667 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,000,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
EXECUTION VERSION 5,000,000 Shares CONTRAFECT CORPORATION Common Stock PURCHASE AGREEMENT July 27, 2018 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. Minneapolis, Minnesota 55402...Purchase Agreement • May 5th, 2020 • New York
ContraFect Corporation, a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,000,000 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 5,000,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 750,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Agreement are herein collectively called the “Shares”.
2,385,000 Shares CUTERA, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • April 21st, 2020 • Cutera Inc • Electromedical & electrotherapeutic apparatus • New York
Cutera, Inc., a Delaware corporation (the “Company”) proposes to sell to Piper Sandler & Co. (the “Underwriter”) an aggregate of 2,385,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the Underwriter an option to purchase up to 357,750 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
RICEBRAN TECHNOLOGIES 5,900,000 Shares of Common Stock1 PURCHASE AGREEMENTPurchase Agreement • December 19th, 2019 • RiceBran Technologies • Grain mill products • New York
RiceBran Technologies, a California corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,900,000 authorized but unissued shares (the “Firm Shares”) of Common Stock, no par value per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the several Underwriters an option to purchase up to 885,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares, and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
3,333,334 Shares ARAVIVE, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • November 27th, 2019 • Aravive, Inc. • Pharmaceutical preparations • New York
Aravive, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,333,334 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 3,333,334 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 500,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Agreement are herein collectively called the “Shares.”
PURCHASE AGREEMENTPurchase Agreement • November 14th, 2019 • Fulgent Genetics, Inc. • Services-medical laboratories • New York
PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402
3,175,652 Shares1 Qumu Corporation Common Stock, par value $0.01 per share PURCHASE AGREEMENTPurchase Agreement • November 8th, 2019 • Qumu Corp • Services-prepackaged software • New York
Qumu Corporation, a Minnesota corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,175,652 shares (the “Firm Shares”) of Common Stock, par value $0.01 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 476,348 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
10,900,000 Shares1 ALPHATEC HOLDINGS, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • August 2nd, 2019 • Alphatec Holdings, Inc. • Surgical & medical instruments & apparatus • New York
Alphatec Holdings, Inc., Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 10,900,000 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,635,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
6,666,667 Shares Motus GI Holdings, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • June 27th, 2019 • Motus GI Holdings, Inc. • Surgical & medical instruments & apparatus • New York
Motus GI Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,666,667 shares (the “Firm Shares”) of Common Stock, $.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 6,666,667 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,000,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
5,833,334 Shares ROCKWELL MEDICAL, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • June 20th, 2019 • Rockwell Medical, Inc. • Electromedical & electrotherapeutic apparatus • New York
Rockwell Medical, Inc., a Michigan corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,833,334 shares (the “Firm Shares”) of common stock, no par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 875,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
4,848,485 Shares1 XBiotech Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • June 3rd, 2019 • XBiotech Inc. • Pharmaceutical preparations • New York
XBiotech Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), proposes to sell to Piper Jaffray & Co. (the “Underwriter”) an aggregate of 4,848,485 shares (the “Firm Shares”) of the common shares, no par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 4,848,485 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the Underwriter an option to purchase up to 351,515 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
Common Stock, par value $0.001 per share PURCHASE AGREEMENTPurchase Agreement • May 24th, 2019 • Liqtech International Inc • Misc industrial & commercial machinery & equipment • New York
LiqTech International, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,931,035 authorized but unissued shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to 284,827 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
9,333,334 Shares1 OncoCyte Corporation Common Stock PURCHASE AGREEMENTPurchase Agreement • February 12th, 2019 • OncoCyte Corp • In vitro & in vivo diagnostic substances • New York
OncoCyte Corporation, a California corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,333,334 shares (the “Firm Shares”) of Common Stock, no par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 9,333,334 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,400,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
5,000,000 Shares Motus GI Holdings, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • December 20th, 2018 • Motus GI Holdings, Inc. • Surgical & medical instruments & apparatus • New York
Motus GI Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,000,000 shares (the “Firm Shares”) of Common Stock, $.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 5,000,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 750,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
Shares Motus GI Holdings, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • December 17th, 2018 • Motus GI Holdings, Inc. • Surgical & medical instruments & apparatus • New York
